Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Thalictrum (Thalictrum squarrosum steph) extract or a fraction thereof as an active ingredient.

An extract from leaves of mulberry is disclosed. The extract has an IC50 value sufficient to inhibit a-glucosidase I. The extract may comprise 5-40%(w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.

An extract from leaves of mulberry is disclosed. The extract has an IC50 value sufficient to inhibit a-glucosidase I. The extract may comprise 5-40%(w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.

The present invention relates to collagen hydrolysate for use as an active substance in the treatment of inflammatory skin disorders and intestinal disorders and/or skin disorders and intestinal disorders accompanied by inflammation.

The present invention relates to collagen hydrolysate for use as an active substance in the treatment of inflammatory skin disorders and intestinal disorders and/or skin disorders and intestinal disorders accompanied by inflammation.

The present disclosure relates to a composition for preventing, improving or treating pruritus by using a naturally derived ingredient. The composition of the present disclosure may be used to improve or treat pruritus caused by various causes safely and effectively without the risk of side effects.

The present invention relates to a biotechnological process for the production of a fermented pollen comprising the inoculation of pollen with at least one lactic bacterium of the species Lactobacillus kunkeei selected from Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) and the fermentation of the pollen inoculated with said lactic bacterium. The fermented pollen obtained has nutritional and organoleptic properties similar to bee bread naturally produced inside the honeycomb of the beehive and finds application in the food and nutraceutical field. The invention further encompasses Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) as such and compositions comprising these strains.

The present invention relates to a biotechnological process for the production of a fermented pollen comprising the inoculation of pollen with at least one lactic bacterium of the species Lactobacillus kunkeei selected from Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) and the fermentation of the pollen inoculated with said lactic bacterium. The fermented pollen obtained has nutritional and organoleptic properties similar to bee bread naturally produced inside the honeycomb of the beehive and finds application in the food and nutraceutical field. The invention further encompasses Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) as such and compositions comprising these strains.

The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.